Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
StimuBlast + platelet-rich plasma
- Development stage
- Unknown
- Lead developer
- Arthrex
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intraarticular
01
Overview
StimuBlast + platelet-rich plasma (PRP) is a combination therapeutic approach used to enhance bone-to-tendon healing in orthopedic procedures, specifically Anterior Cruciate Ligament (ACL) reconstruction. StimuBlast is a commercially available demineralized bone matrix (DBM) that serves as an osteoconductive scaffold and contains endogenous bone morphogenetic proteins (BMPs) that provide osteoinductive signals for bone formation. PRP is an autologous concentration of platelets derived from the patient's own blood, which, upon activation, releases a cocktail of growth factors including PDGF, TGF-β, and VEGF. In the context of ACL surgery, this "Osteoinductive/Osteoconductive Compound" (OOC) is injected or applied to the bone tunnels to accelerate graft maturation and integration, aiming to improve clinical outcomes and support accelerated rehabilitation protocols.
- Other names
- Osteoinductive/Osteoconductive CompoundPRPPlatelet-Rich PlasmaDBMDemineralized Bone Matrix
02
Targets
BMPR (Bone morphogenetic protein receptor)α10β1 (Integrin alpha 10 beta 1)FGFR (FGFR family)IGF-1R (Insulin-like growth factor 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)TGFBR (TGF-beta receptor)VEGFR (VEGFR family)
Beyond the preview
Go deeper on StimuBlast + platelet-rich plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on StimuBlast + platelet-rich plasma.